Pharmaceutical Pricing and Reimbursement Regulation in Europe-Reference-Cited by-同舟云学术

Pharmaceutical Pricing and Reimbursement Regulation in Europe

Published:2014 Issue: Volume: Page:29-36
ISSN:
Container-title:Encyclopedia of Health Economics
language:
Short-container-title:

Author:

Stargardt T.,Vandoros S.

Publisher

Elsevier

Reference28 articles.

1. Prescribing behaviour after the introduction of decentralized drug budgets: Is there an association with employer and type of care facility?;Andersson;Scandinavian Journal of Primary Health Care,2009

2. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry;Barros;Health Economics,2011

3. Availability of and access to orphan drugs: An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia;Blankart;PharmacoEconomics,2011

4. Pharmaceutical risk-sharing agreements;Cook;PharmacoEconomics,2008

5. Danzon, P. M. and Epstein, A. J. (2009). Launch and pricing strategies of pharmaceuticals in interdependent markets. NBER Working paper. Cambridge, MA: National Bureau of Economic Research.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation;PLOS ONE;2024-05-02

2. Leistungsmanagement;Management im Gesundheitswesen;2022

3. The impact of physician-level drug budgets on prescribing behavior;The European Journal of Health Economics;2017-02-13

4. Leistungsmanagement;Management im Gesundheitswesen;2017

5. The diffusion of generics after patent expiry in Germany;The European Journal of Health Economics;2015-11-16